SMAD2 and hepatocellular carcinoma: Previous studies based on 12 year follow-up demonstrated that chronic HBV/HCV patients with P-Smad2/3L in liver tissues had a higher risk of advancing to hepatocellular carcinoma (HCC) than those with P-Smad2/3C [8], [21].